6LJ Stock Chart & Stats
€0.05
>-€0.01(-14.52%)
At close: 4:00 PM EST
€0.05
>-€0.01(-14.52%)
Day’s Range― - ―
52-Week Range€0.05 - €0.05
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€2.11M
Enterprise Value€1.94
Total Cash (Recent Filing)€761.00K
Total Debt (Recent Filing)€6.00K
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding979,520
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.66
Price to Sales (P/S)0.00
P/FCF Ratio-0.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Minimal LeverageMinimal debt reduces solvency pressure and leaves fewer mandatory claims on a very small operating base. This gives Matinas greater flexibility than a highly leveraged biotech, although the benefit is limited because the company still consumes cash and lacks revenue.
Reduced Loss And Cash-burn IntensityThe improvement in losses and cash usage shows some progress in controlling financial deterioration compared with prior years. If sustained, lower burn could extend funding runway and reduce financing pressure, though the company remains unprofitable and cash flow is still negative.
Strategic Repositioning And Potential ProceedsThe planned asset sale could provide upfront cash, milestone payments, and royalties, while the proposed GH Power combination would reposition the listed entity around a different operating platform. These actions may create a new strategic path, but remain subject to closing conditions.
Bears Say
No Commercial Revenue And Persistent LossesThe absence of meaningful revenue means Matinas has not established a commercial funding engine for its operations. Persistent losses, including a roughly $7.3 million TTM net loss, leave future progress dependent on external financing, transactions, or successful product development.
Ongoing Negative Cash GenerationContinued operating and free-cash-flow losses show that the business is not self-funding over the current period. Even with lower burn than in earlier years, ongoing cash consumption can require additional capital and may pressure strategic choices, ownership, and development priorities.
Listing Compliance And Delisting RiskThe exchange notice reflects a structurally weakened equity base and a long record of losses, creating an ongoing risk to market access. Although the remediation plan permits continued listing for now, failure to restore compliance could lead to delisting proceedings and reduce financing flexibility.
Matinas BioPharma News
6LJ FAQ
What was Matinas BioPharma’s price range in the past 12 months?
Matinas BioPharma lowest stock price was €0.05 and its highest was €0.05 in the past 12 months.
What is Matinas BioPharma’s market cap?
Matinas BioPharma’s market cap is €2.11M.
When is Matinas BioPharma’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Matinas BioPharma’s earnings last quarter?
Currently, no data Available
Is Matinas BioPharma overvalued?
According to Wall Street analysts Matinas BioPharma’s price is currently Overvalued.
Does Matinas BioPharma pay dividends?
Matinas BioPharma does not currently pay dividends.
What is Matinas BioPharma’s EPS estimate?
Matinas BioPharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Matinas BioPharma have?
Matinas BioPharma has 979,520 shares outstanding.
What happened to Matinas BioPharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Matinas BioPharma?
Currently, no hedge funds are holding shares in DE:6LJ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Matinas BioPharma
Matinas BioPharma Holdings, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying and advancing a range of potential therapeutic products. The company's innovative Lipid Nanocrystal (LNC) platform technology underpins its product development efforts. This sophisticated LNC delivery system leverages lipid nano-crystals to transport a diverse array of therapeutic agents, including small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its primary experimental drug, LYPDISO, is a proprietary, prescription-grade omega-3 free fatty acid compound engineered to address cardiovascular and metabolic disorders. Matinas BioPharma is also advancing MAT2203, an orally administered version of amphotericin B. This candidate is currently in Phase II clinical trials, where it is being evaluated for its ability to prevent invasive fungal infections in patients undergoing immunosuppressive treatment. Furthermore, MAT2501, an oral formulation of the broad-spectrum aminoglycoside antibiotic amikacin, has successfully completed Phase I clinical trials. Its aim is to combat a spectrum of multidrug-resistant bacterial infections, such as non-tuberculous mycobacterium, multidrug-resistant gram-negative, and intracellular bacterial pathogens. The company actively engages in collaborations, including a research partnership with the National Institute of Allergy and Infectious Diseases (NIAID) to further the development of Gilead's antiviral drug, remdesivir. Additionally, it has a feasibility collaboration with Genentech, Inc. focused on creating new oral drug formulations. Established in 2013, Matinas BioPharma maintains its corporate headquarters in Bedminster, New Jersey.